20th Hemoglobin Switching Conference

第20届血红蛋白转换会议

• 批准号: 9197787
• 负责人: James Douglas Engel
• 金额: $ 5.5万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9197787
• 关键词: American Society of Hematology; Anabolism; Back; Biochemical; Biochemistry; California; Carbon Dioxide; Cell Differentiation process; Cells; Cellular biology; Clinical; Collaborations; Complementary DNA; Development; Developmental Biology; Disease; Epigenetic Process; Erythrocytes; Erythropoietin; Etiology; Europe; Faculty; Family; Fertilization; Gene Expression Regulation; Genetic; Genomics; Globin; Great Britain; Hematology; Hematopoietic; Hemoglobin; Hemoglobinopathies; Hereditary Disease; Human Cloning; Human Genetics; Inherited; International; Lung; Metabolic Diseases; Metabolism; Minority; Molecular; Molecular Biology; Mutation; Oxygen; Participant; Physiology; Postdoctoral Fellow; Process; Research; Research Personnel; Science; Scientist; Site; Structure; Students; Time; Tissues; Woman; Work; abstracting; career; disease phenotype; effective therapy; man; meetings; novel; phenomenological models; success; symposium; transcription factor

Abstract The biennial Hemoglobin Switching Conference has been ongoing for 39 years, and there are multiple reasons for its resounding success. First and foremost, the organizers (Stamatoyannopoulos, Higgs and Engel) strive to identify and then highlight new discoveries by always including new, young investigators and studies that impinge on the process of globin biosynthesis. Second, this is the only venue (other than the annual ASH meeting, with more than 14,000 participants) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, the hemoglobinopathies, the most common inherited diseases in man. Third, the meetings have historically evolved with intense focus on wherever the science led, thus remaining extremely topical, and has not only been the forum for presenting the first cDNA clones, the first cloned human genomic locus (and the first mutations in same), the structure of erythropoietin and the discovery of the GATA and KLF transcription factor families, but it has also launched the careers of many of the current leaders in this field (indeed, numerous postdoctoral fellows and young faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximately equal attendance by investigators from both inside and outside the U.S., and this fact is reflected by the biennial alternation in site between the U.S. and Europe. In 2016 the Conference will be held for the third time at the Asilomar Conference Center in California, because of both the ease of international accessibility and economy.

摘要 两年一度的血红蛋白转换会议已经持续了39年， 它的巨大成功有多种原因。首先，组织者（Stamatoyannopoulos， 希格斯和恩格尔）努力识别，然后突出新的发现，总是包括新的，年轻的， 对珠蛋白生物合成过程产生影响的调查者和研究。第二，这是唯一的 地点（除了年度会议，有14，000多名与会者），汇集了 基础科学家和临床医生讨论的分子和发育起源， 血红蛋白病是人类最常见的遗传性疾病。第三， 历史上，会议一直在不断发展，重点关注科学的发展方向，因此， 非常热门，不仅是展示第一个cDNA克隆的论坛，也是第一个克隆的 人类基因组基因座（以及其中的第一个突变），促红细胞生成素的结构和促红细胞生成素的结构。 加塔和KLF转录因子家族的发现，但它也启动了 许多目前在这一领域的领导者（事实上，许多博士后研究员和年轻的教师首先 在这次会议的全体会议上介绍了他们的工作）。第四，这是唯一一次关于这个问题的会议， 内部和外部的调查人员通常参加的人数大致相等的主题 美国，这一事实反映在美国和欧洲两年一次的地点交替上。在 2016年会议将在加州的Asilomar会议中心举行第三次， 因为国际交通便利和经济。